Sprint Bioscience Q3 Operating Loss Widens 75% to SEK 14.74 Million

PUBT · 2d ago
Sprint Bioscience Q3 Operating Loss Widens 75% to SEK 14.74 Million
  • Sprint Bioscience’s third-quarter 2026 loss after tax widened 68% year-over-year to SEK 14.16 million.
  • There were no net sales, compared with SEK 5.24 million a year earlier.
  • Cash rose year-over-year to SEK 77.52 million at September 30, 2026.
  • A July agreement with Lilly TuneLab provides access to AI-driven predictive models to accelerate drug development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.